Old Articles: <Older 8231-8240 Newer> |
|
The Motley Fool January 12, 2012 Brian Orelli |
What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see. |
Chemistry World January 11, 2012 Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
IndustryWeek January 11, 2012 |
Northeast Indiana's Instrumental Assets Medical-device manufacturers are finding the 10-county Northeast Indiana region a prime location with a skilled workforce. |
IndustryWeek January 11, 2012 |
Life Technologies: IW Best Plants Profile 2011 This plant transformation created a true manufacturing environment in a science-based culture and major revenue wins. |
The Motley Fool January 11, 2012 Brian Orelli |
A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running. |
The Motley Fool January 11, 2012 Dan Caplinger |
Has Arena Pharmaceuticals Become the Perfect Stock? Since we looked at Arena Pharmaceuticals last year revenue has fallen back and debt-to-equity levels have soared. |
The Motley Fool January 10, 2012 Sean Williams |
Could This Stock Nearly Double 2 Years In a Row? Up 96% in 2011, there's a decent chance at a Jazz Pharmaceuticals repeat in 2012. |
The Motley Fool January 10, 2012 Sean Williams |
2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair. |
The Motley Fool January 10, 2012 Matt Koppenheffer |
Health Management Shares Got Crushed: What You Need to Know Shares of hospital operator Health Management Associates were looking seriously ill today, as they fell as much as 31% after the company's general counsel abruptly resigned. |
The Motley Fool January 10, 2012 Sean Williams |
Idenix Pharmaceuticals Shares Skyrocketed Again: What You Need to Know Shares of hepatitis-C drug hopeful Idenix Pharmaceuticals are continuing their rally for a second day, currently up 21%, as speculation swirls that it will be the next takeover candidate. |
<Older 8231-8240 Newer> Return to current articles. |